◎ Sugi Atlas

Atlas / Gene / H3C1

H3C1

gene
On this page

Also known as H3/A

Summary

H3C1 (H3 clustered histone 1, HGNC:4766) is a protein-coding gene on chromosome 6p22.2, encoding Histone H3.1 (P68431). Core component of nucleosome.

Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. This structure consists of approximately 146 bp of DNA wrapped around a nucleosome, an octamer composed of pairs of each of the four core histones (H2A, H2B, H3, and H4). The chromatin fiber is further compacted through the interaction of a linker histone, H1, with the DNA between the nucleosomes to form higher order chromatin structures. This gene is intronless and encodes a replication-dependent histone that is a member of the histone H3 family. Transcripts from this gene lack polyA tails; instead, they contain a palindromic termination element. This gene is found in the large histone gene cluster on chromosome 6p22-p21.3.

Source: NCBI Gene 8350 — RefSeq curated summary.

At a glance

  • GWAS associations: 18
  • Clinical variants (ClinVar): 46 total — 1 likely-pathogenic
  • MANE Select transcript: NM_003529

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:4766
Approved symbolH3C1
NameH3 clustered histone 1
Location6p22.2
Locus typegene with protein product
StatusApproved
AliasesH3/A
Ensembl geneENSG00000275714
Ensembl biotypeprotein_coding
OMIM602810
Entrez8350

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000613854, ENST00000850876

RefSeq mRNA: 1 — MANE Select: NM_003529 NM_003529

CCDS: CCDS4570

Canonical transcript exons

ENST00000613854 — 1 exons

ExonStartEnd
ENSE000037501522602045126020958

Expression profiles

Bgee: expression breadth ubiquitous, 150 present calls, max score 92.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 266.0473 / max 5289.5639, expressed in 1768 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter IDTPM avgSamples expressed
66461266.04731768

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
bone marrow cellCL:000209292.85gold quality
primordial germ cell in gonadCL:0000670 ∩ UBERON:000099187.23gold quality
male germ line stem cell (sensu Vertebrata) in testisCL:0000089 ∩ UBERON:000047384.20gold quality
adrenal tissueUBERON:001830383.09gold quality
calcaneal tendonUBERON:000370179.74gold quality
granulocyteCL:000009467.17gold quality
tendonUBERON:000004364.86gold quality
left testisUBERON:000453363.91gold quality
monocyteCL:000057663.71gold quality
right testisUBERON:000453462.69gold quality
colonic epitheliumUBERON:000039762.20silver quality
testisUBERON:000047362.15gold quality
leukocyteCL:000073862.08gold quality
bone marrowUBERON:000237161.92gold quality
oocyteCL:000002356.76gold quality
mucosa of transverse colonUBERON:000499155.93gold quality
tonsilUBERON:000237255.66gold quality
olfactory segment of nasal mucosaUBERON:000538653.99gold quality
islet of LangerhansUBERON:000000653.72gold quality
bloodUBERON:000017852.88gold quality
mucosa of stomachUBERON:000119952.21gold quality
right coronary arteryUBERON:000162551.68gold quality
corpus callosumUBERON:000233649.00gold quality
descending thoracic aortaUBERON:000234548.54gold quality
uterine cervixUBERON:000000248.42gold quality
adrenal glandUBERON:000236948.10gold quality
right atrium auricular regionUBERON:000663148.08gold quality
cardiac atriumUBERON:000208147.88gold quality
rectumUBERON:000105247.74gold quality
stomachUBERON:000094547.34gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

ExperimentMarker?Max mean expression
E-ANND-3no2.20

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): BCL11A, TP53

Literature-anchored findings (GeneRIF, showing 40)

  • The authors report that de novo CENP-A assembly and kinetochore formation on human centromeric alphoid DNA arrays is regulated by a histone H3K9 acetyl/methyl balance. (PMID:22473132)
  • Data indicate that inhibition of lysine-specific demethylase 1 activity prevented IL-1beta-induced histone H3 lysine 9 (H3K9) demethylation at microsomal prostaglandin E synthase 1 (mPGES-1) promoter. (PMID:24886859)
  • Data show that double mutations on the residues in the interface (L325A/D328A) decreases the histone H3 H3K4me2/3 demethylation activity of lysine (K)-specific demethylase 5B (KDM5B). (PMID:24952722)
  • Data indicate that the lower-resolution mass spectrometry instruments can be utilized for histone post-translational modifications (PTMs) analysis. (PMID:25325711)
  • Functional importance of H3K9me3 in hypoxia, apoptosis and repression of APAK. (PMID:25961932)
  • Taken together, the authors verified that histone H3 is a real substrate for GzmA in vivo in the Raji cells treated by staurosporin. (PMID:26032366)
  • PIP5K1A modulates ribosomal RNA gene silencing through its interaction with histone H3 lysine 9 trimethylation and heterochromatin protein HP1-alpha. (PMID:26157143)
  • Data indicate that minichromosome maintenance protein 2 (MCM2) binding is not required for incorporation of histone H3.1-H4 into chromatin but is important for stability of H3.1-H4. (PMID:26167883)
  • Data suggest that histone H3 lysine methylation (H3K4me3) serves a crucial mechanistic role in leukemia stem cell (LSC) maintenance (PMID:26190263)
  • We conclude that circulating H3 levels correlate with mortality in sepsis patients and inversely correlate with antithrombin levels and platelet counts. (PMID:26232351)
  • This series of 47 diffuse midline gliomas, histone H3-K27M mutation was mutually exclusive with IDH1-R132H mutation and EGFR amplification, rarely co-occurred with BRAF-V600E mutation, and was commonly associated with p53 overexpression, ATRX loss, and monosomy 10. Among these K27M+ diffuse midline gliomas. (PMID:26517431)
  • Data show that H3K36me3-deficient cancers can be targeted by inhibition of WEE1 protein. (PMID:26602815)
  • AS1eRNA-driven DNA looping and activating histone modifications promote the expression of DHRS4-AS1 to economically control the DHRS4 gene cluster. (PMID:26864944)
  • The authors propose that histone H3 threonine 118 phosphorylation via Aurora-A alters the chromatin structure during specific phases of mitosis to promote timely condensin I and cohesin disassociation, which is essential for effective chromosome segregation. (PMID:26878753)
  • Hemi-methylated DNA opens a closed conformation of UHRF1 to facilitate its H3 histone recognition. (PMID:27045799)
  • Data suggest that nuclear antigen Sp100C is a multifaceted histone H3 methylation and phosphorylation sensor. (PMID:27129259)
  • Approximately 30% of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome and was shown to influence EZH2 function. (PMID:27135271)
  • These experiments showed that PHF13 binds specifically to DNA and to two types of histone H3 methyl tags (lysine 4-tri-methyl or lysine 4-di-methyl) where it functions as a transcriptional co-regulator. (PMID:27223324)
  • This data indicates that, in the early developing human brain, HIST1H3B constitutes the largest proportion of H3.1 transcripts among H3.1 isoforms. (PMID:27251074)
  • Histone H3 lysine 9 (H3K9) acetylation was most prevalent when the Dbf4 transcription level was highest whereas the H3K9me3 level was greatest during and just after replication. (PMID:27341472)
  • Hemi-methylated CpGs DNA recognition activates UHRF1 ubiquitylation towards multiple lysines on the H3 tail adjacent to the UHRF1 histone-binding site. (PMID:27595565)
  • SPOP-containing complex regulates SETD2 stability and H3K36me3-coupled alternative splicing. (PMID:27614073)
  • These results identify cytokine-induced histone 3 lysine 27 trimethylation as a mechanism that stabilizes gene silencing in macrophages (PMID:27653678)
  • The results demonstrate a novel mechanism by which Kdm4d regulates DNA replication by reducing the H3K9me3 level to facilitate formation of preinitiation complex. (PMID:27679476)
  • hTERT promoter mutations are frequent in medulloblastoma and are associated with older patients, prone to recurrence and located in the right cerebellar hemisphere. On the other hand, histone 3 mutations do not seem to be present in medulloblastoma. (PMID:27694758)
  • Data show that lysyl oxidase-like 2 (LOXL2) is a histone modifier enzyme that removes trimethylated lysine 4 (K4) in histone H3 (H3K4me3) through an amino-oxidase reaction. (PMID:27735137)
  • Histone H3 modifications caused by traffic-derived airborne particulate matter exposures in leukocytes (PMID:27918982)
  • A key role of persistent histone H3 serine 10 or serine 28 phosphorylation in chemical carcinogenesis through regulating gene transcription of DNA damage response genes (PMID:27996159)
  • We describe, for the first time, the MR imaging features of pediatric diffuse midline gliomas with histone H3 K27M mutation (PMID:28183840)
  • Data indicate the mechanism for epigenetic regulation in cancer by inducing E3 ubiquitin ligase NEDD4-dependent histone H3 ubiquitination. (PMID:28300060)
  • Data suggest that binding of helical tail of histone 3 (H3) with PHD (‘plant homeodomain’) fingers of BAZ2A or BAZ2B (bromodomain adjacent to zinc finger domain 2A or 2B) requires molecular recognition of secondary structure motifs within H3 tail and could represent an additional layer of regulation in epigenetic processes. (PMID:28341809)
  • H3F3A K27M mutation in adult cerebellar HGG is not rare. (PMID:28547652)
  • Data show that histone chaperone HIRA co-localizes with viral genomes, binds to incoming viral and deposits histone H3.3 onto these. (PMID:28981850)
  • Here, we report that JMJD5, a Jumonji C (JmjC) domain-containing protein, is a Cathepsin L-type protease that mediates histone H3 N-tail proteolytic cleavage under stress conditions that cause a DNA damage response. (PMID:28982940)
  • Data suggest that Ki-67 antigen proliferative index has important limitations and hhosphohistone H3 (PHH3) is an alternative proliferative marker. (PMID:29040195)
  • the identification of increased expression of H3K27me3 during a patient’s clinical course can be helpful for determining whether the tumors are heterochronous (PMID:29482987)
  • the H3 K27M mutation was mainly associated with a poorer prognosis in infratentorial gliomas compared with the corresponding H3 wild-type gliomas (PMID:29727696)
  • In 2 cases, we identified H3F3A mutation, classically described in pediatric midline gliomas (PMID:29809131)
  • Enhancer activity requires CBP/P300 bromodomain-dependent histone H3K27 acetylation. (PMID:30110629)
  • CSB reduces H3K9me3 chromatin remodeler SETDB1 and exacerbates cellular aging. (PMID:31276581)

Cross-species orthologs

24 orthologs

OrganismSymbolGene ID
danio_reriozgc:173552ENSDARG00000051737
danio_reriosi:ch1073-153i20.2ENSDARG00000105345
danio_reriozgc:173552ENSDARG00000110909
danio_reriosi:ch211-113a14.27ENSDARG00000111396
danio_reriosi:ch211-113a14.20ENSDARG00000112131
danio_reriozgc:173552ENSDARG00000112175
danio_reriosi:ch211-113a14.23ENSDARG00000114334
mus_musculusH3c1ENSMUSG00000069265
drosophila_melanogasterHis3:CG33812FBGN0053812
caenorhabditis_elegansWBGENE00001876
caenorhabditis_elegansWBGENE00001880
caenorhabditis_elegansWBGENE00001883
caenorhabditis_elegansWBGENE00001887
caenorhabditis_elegansWBGENE00001891
caenorhabditis_elegansWBGENE00001899
caenorhabditis_elegansWBGENE00001901
caenorhabditis_elegansWBGENE00001906
caenorhabditis_elegansWBGENE00001914
caenorhabditis_elegansWBGENE00001916
caenorhabditis_elegansWBGENE00001919
caenorhabditis_elegansWBGENE00001923
caenorhabditis_elegansWBGENE00001929
caenorhabditis_elegansWBGENE00001933
caenorhabditis_elegansWBGENE00001937

Paralogs (20): CENPA (ENSG00000115163), H3-3B (ENSG00000132475), H3-3A (ENSG00000163041), H3-4 (ENSG00000168148), H3C13 (ENSG00000183598), H3-5 (ENSG00000188375), H3C12 (ENSG00000197153), H3C4 (ENSG00000197409), H3C14 (ENSG00000203811), H3C15 (ENSG00000203852), H3Y2 (ENSG00000268799), H3Y1 (ENSG00000269466), H3-7 (ENSG00000273213), H3C8 (ENSG00000273983), H3C6 (ENSG00000274750), H3C11 (ENSG00000275379), H3C7 (ENSG00000277775), H3C10 (ENSG00000278828), H3C2 (ENSG00000286522), H3C3 (ENSG00000287080)

Protein

Protein identifiers

Histone H3.1 — P68431 (reviewed: P68431)

Alternative names: Histone H3/a, Histone H3/b, Histone H3/c, Histone H3/d, Histone H3/f, Histone H3/h, Histone H3/i, Histone H3/j, Histone H3/k, Histone H3/l

All UniProt accessions (1): P68431

UniProt curated annotations — full annotation on UniProt →

Function. Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling.

Subunit / interactions. The nucleosome is a histone octamer containing two molecules each of H2A, H2B, H3 and H4 assembled in one H3-H4 heterotetramer and two H2A-H2B heterodimers. The octamer wraps approximately 147 bp of DNA. Interacts with TONSL; CHAF1A; CHAF1B; MCM2 and DNAJC9. Interacts with NASP; NASP is a histone chaperone that stabilizes and maintains a soluble pool of Histone H3-H4 dimers.

Subcellular location. Nucleus. Chromosome.

Post-translational modifications. Acetylation is generally linked to gene activation. Acetylation on Lys-10 (H3K9ac) impairs methylation at Arg-9 (H3R8me2s). Acetylation on Lys-19 (H3K18ac) and Lys-24 (H3K24ac) favors methylation at Arg-18 (H3R17me). Acetylation at Lys-123 (H3K122ac) by EP300/p300 plays a central role in chromatin structure: localizes at the surface of the histone octamer and stimulates transcription, possibly by promoting nucleosome instability. Citrullination at Arg-9 (H3R8ci) and/or Arg-18 (H3R17ci) by PADI4 impairs methylation and represses transcription. Asymmetric dimethylation at Arg-18 (H3R17me2a) by CARM1 is linked to gene activation. Symmetric dimethylation at Arg-9 (H3R8me2s) by PRMT5 is linked to gene repression. Asymmetric dimethylation at Arg-3 (H3R2me2a) by PRMT6 is linked to gene repression and is mutually exclusive with H3 Lys-5 methylation (H3K4me2 and H3K4me3). H3R2me2a is present at the 3’ of genes regardless of their transcription state and is enriched on inactive promoters, while it is absent on active promoters. Methylation at Lys-5 (H3K4me), Lys-37 (H3K36me) and Lys-80 (H3K79me) are linked to gene activation. Methylation at Lys-5 (H3K4me) facilitates subsequent acetylation of H3 and H4. Methylation at Lys-80 (H3K79me) is associated with DNA double-strand break (DSB) responses and is a specific target for TP53BP1. Methylation at Lys-10 (H3K9me) and Lys-28 (H3K27me) are linked to gene repression. Methylation at Lys-10 (H3K9me) is a specific target for HP1 proteins (CBX1, CBX3 and CBX5) and prevents subsequent phosphorylation at Ser-11 (H3S10ph) and acetylation of H3 and H4. Methylation at Lys-5 (H3K4me) and Lys-80 (H3K79me) require preliminary monoubiquitination of H2B at ‘Lys-120’. Methylation at Lys-10 (H3K9me) and Lys-28 (H3K27me) are enriched in inactive X chromosome chromatin. Monomethylation at Lys-57 (H3K56me1) by EHMT2/G9A in G1 phase promotes interaction with PCNA and is required for DNA replication. Phosphorylated at Thr-4 (H3T3ph) by VRK1. Phosphorylated at Thr-4 (H3T3ph) by HASPIN during prophase and dephosphorylated during anaphase. Phosphorylation at Ser-11 (H3S10ph) by AURKB is crucial for chromosome condensation and cell-cycle progression during mitosis and meiosis. In addition phosphorylation at Ser-11 (H3S10ph) by RPS6KA4 and RPS6KA5 is important during interphase because it enables the transcription of genes following external stimulation, like mitogens, stress, growth factors or UV irradiation and result in the activation of genes, such as c-fos and c-jun. Phosphorylation at Ser-11 (H3S10ph), which is linked to gene activation, prevents methylation at Lys-10 (H3K9me) but facilitates acetylation of H3 and H4. Phosphorylation at Ser-11 (H3S10ph) by AURKB mediates the dissociation of HP1 proteins (CBX1, CBX3 and CBX5) from heterochromatin. Phosphorylation at Ser-11 (H3S10ph) is also an essential regulatory mechanism for neoplastic cell transformation. Phosphorylated at Ser-29 (H3S28ph) by MAP3K20 isoform 1, RPS6KA5 or AURKB during mitosis or upon ultraviolet B irradiation. Phosphorylation at Thr-7 (H3T6ph) by PRKCB is a specific tag for epigenetic transcriptional activation that prevents demethylation of Lys-5 (H3K4me) by LSD1/KDM1A. At centromeres, specifically phosphorylated at Thr-12 (H3T11ph) from prophase to early anaphase, by DAPK3 and PKN1. Phosphorylation at Thr-12 (H3T11ph) by PKN1 or isoform M2 of PKM (PKM2) is a specific tag for epigenetic transcriptional activation that promotes demethylation of Lys-10 (H3K9me) by KDM4C/JMJD2C. Phosphorylation at Thr-12 (H3T11ph) by chromatin-associated CHEK1 regulates the transcription of cell cycle regulatory genes by modulating acetylation of Lys-10 (H3K9ac). Phosphorylation at Tyr-42 (H3Y41ph) by JAK2 promotes exclusion of CBX5 (HP1 alpha) from chromatin. Monoubiquitinated at Lys-15 (H3K14ub), Lys-19 (H3K18ub) and Lys-24 (H3K23ub) by UHRF1 and HLTF at hemimethylated DNA sites following DNA replication, promoting recruitment of DNMT1 DNA methyltransferase and replication-coupled DNA methylation maintenance. Monoubiquitinated by RAG1 in lymphoid cells, monoubiquitination is required for V(D)J recombination. Ubiquitinated by the CUL4-DDB-RBX1 complex in response to ultraviolet irradiation. This may weaken the interaction between histones and DNA and facilitate DNA accessibility to repair proteins. Lysine deamination at Lys-5 (H3K4all) to form allysine is mediated by LOXL2. Allysine formation by LOXL2 only takes place on H3K4me3 and results in gene repression. Crotonylation (Kcr) is specifically present in male germ cells and marks testis-specific genes in post-meiotic cells, including X-linked genes that escape sex chromosome inactivation in haploid cells. Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors. It is also associated with post-meiotically activated genes on autosomes. Butyrylation of histones marks active promoters and competes with histone acetylation. It is present during late spermatogenesis. Succinylation at Lys-80 (H3K79succ) by KAT2A takes place with a maximum frequency around the transcription start sites of genes. It gives a specific tag for epigenetic transcription activation. Desuccinylation at Lys-123 (H3K122succ) by SIRT7 in response to DNA damage promotes chromatin condensation and double-strand breaks (DSBs) repair. Serine ADP-ribosylation by PARP1 or PARP2 constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage. Serine ADP-ribosylation at Ser-11 (H3S10ADPr) promotes recruitment of CHD1L. H3S10ADPr is mutually exclusive with phosphorylation at Ser-11 (H3S10ph) and impairs acetylation at Lys-10 (H3K9ac). Serotonylated by TGM2 at Gln-6 (H3Q5ser) during serotonergic neuron differentiation. H3Q5ser is associated with trimethylation of Lys-5 (H3K4me3) and enhances general transcription factor IID (TFIID) complex-binding to H3K4me3, thereby facilitating transcription. Dopaminylated by TGM2 at Gln-6 (H3Q5dop) in ventral tegmental area (VTA) neurons. H3Q5dop mediates neurotransmission-independent role of nuclear dopamine by regulating relapse-related transcriptional plasticity in the reward system. Lactylated in macrophages by EP300/P300 by using lactoyl-CoA directly derived from endogenous or exogenous lactate, leading to stimulates gene transcription.

Disease relevance. Glioma (GLM) [MIM:137800] Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. The gene represented in this entry is involved in disease pathogenesis. HIST1H3B mutations affecting residue Lys-28 involved in post-translational modifications of histone H3.1 are recurrent in malignant, aggressive gliomas including pediatric non-brain stem glioblastoma and diffuse intrinsic pontine glioma (DIPG). The mechanism through which mutations lead to tumorigenesis involves altered histone methylation, impaired regulation of Polycomb repressive complex 2 (PRC2) activity, and aberrant epigenetic regulation of gene expression. HIST1H3B or HIST1H3C mutations affecting residue Lys-37 of histone H3.1 are involved in the pathogenesis of pediatric undifferentiated soft tissue sarcomas. The mechanism through which mutations lead to tumorigenesis involves altered histones methylation with gain of global H3K27 methylation, altered Polycomb repressive complex 1 (PRC1) activity, aberrant epigenetic regulation of gene expression and impaired differentiation of mesenchimal progenitor cells.

Miscellaneous. This histone is only present in mammals and is enriched in acetylation of Lys-15 and dimethylation of Lys-10 (H3K9me2).

Similarity. Belongs to the histone H3 family.

RefSeq proteins (1): NP_003520* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR000164Histone_H3/CENP-AFamily
IPR007125H2A/H2B/H3Domain
IPR009072Histone-foldHomologous_superfamily

Pfam: PF00125

UniProt features (146 total): modified residue 120, strand 8, sequence conflict 4, helix 4, cross-link 3, sequence variant 3, initiator methionine 1, chain 1, lipid moiety-binding region 1, region of interest 1

Structure

Experimental structures (PDB)

548 structures, top 30 by resolution.

PDBMethodResolution (Å)
5SVYX-RAY DIFFRACTION1.05
2V89X-RAY DIFFRACTION1.1
5SZCX-RAY DIFFRACTION1.19
5SZBX-RAY DIFFRACTION1.2
6BHDX-RAY DIFFRACTION1.25
4UP0X-RAY DIFFRACTION1.28
5WXHX-RAY DIFFRACTION1.3
5FFVX-RAY DIFFRACTION1.3
4L7XX-RAY DIFFRACTION1.35
6BHEX-RAY DIFFRACTION1.35
6BHIX-RAY DIFFRACTION1.4
3ASLX-RAY DIFFRACTION1.41
5TDRX-RAY DIFFRACTION1.42
2RI7X-RAY DIFFRACTION1.45
4X3KX-RAY DIFFRACTION1.45
6BHGX-RAY DIFFRACTION1.45
5GH9X-RAY DIFFRACTION1.45
3V43X-RAY DIFFRACTION1.47
5JIYX-RAY DIFFRACTION1.48
8IJ0X-RAY DIFFRACTION1.52
3RIYX-RAY DIFFRACTION1.55
5SVXX-RAY DIFFRACTION1.56
2VPGX-RAY DIFFRACTION1.6
4LK9X-RAY DIFFRACTION1.6
4Y6LX-RAY DIFFRACTION1.6
5T1IX-RAY DIFFRACTION1.6
5U2JX-RAY DIFFRACTION1.6
7CFPX-RAY DIFFRACTION1.6
7CFQX-RAY DIFFRACTION1.6
6V41X-RAY DIFFRACTION1.6

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-P68431-F186.950.71

Antibody-complex structures (SAbDab): 19 — 4YHP, 4YHZ, 7K5X, 7K5Y, 7K60, 7K61, 7K63, 7U0G, 7U0I, 7U0J, 8DK5, 8EVG, 8EVH, 8EVI, 8EVJ, 8SPS, 8SPU, 8SYP, 8VFX

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (124): 5, 80, 80, 80, 80, 80, 80, 80, 80, 80, 80, 5, 81, 87, 108, 116, 116, 123, 123, 123 …

Function

Pathways and Gene Ontology

Reactome pathways

48 pathways

IDPathway
R-HSA-1266695Interleukin-7 signaling
R-HSA-1912408Pre-NOTCH Transcription and Translation
R-HSA-201722Formation of the beta-catenin:TCF transactivating complex
R-HSA-212300PRC2 methylates histones and DNA
R-HSA-2299718Condensation of Prophase Chromosomes
R-HSA-2559580Oxidative Stress Induced Senescence
R-HSA-2559582Senescence-Associated Secretory Phenotype (SASP)
R-HSA-3214815HDACs deacetylate histones
R-HSA-3214841PKMTs methylate histone lysines
R-HSA-3214842HDMs demethylate histones
R-HSA-3214847HATs acetylate histones
R-HSA-3214858RMTs methylate histone arginines
R-HSA-3247509Chromatin modifying enzymes
R-HSA-427359SIRT1 negatively regulates rRNA expression
R-HSA-427389ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
R-HSA-427413NoRC negatively regulates rRNA expression
R-HSA-5250924B-WICH complex positively regulates rRNA expression
R-HSA-5334118DNA methylation
R-HSA-5578749Transcriptional regulation by small RNAs
R-HSA-5617472Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-5625886Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
R-HSA-68616Assembly of the ORC complex at the origin of replication
R-HSA-73728RNA Polymerase I Promoter Opening
R-HSA-73772RNA Polymerase I Promoter Escape
R-HSA-8936459RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
R-HSA-8939236RUNX1 regulates transcription of genes involved in differentiation of HSCs
R-HSA-9018519Estrogen-dependent gene expression
R-HSA-912446Meiotic recombination
R-HSA-9609690HCMV Early Events
R-HSA-9610379HCMV Late Events

MSigDB gene sets: 182 (showing top): REACTOME_MEIOTIC_RECOMBINATION, GOBP_CHROMOSOME_ORGANIZATION, REACTOME_DNA_REPLICATION, REACTOME_SIGNALING_BY_NOTCH, E2F4DP1_01, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_TELOMERE_ORGANIZATION, MEF2_02, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, E2F1DP1_01, E2F1DP2_01, GOBP_PROTEIN_DNA_COMPLEX_ORGANIZATION, GOBP_CHROMATIN_REMODELING

GO Biological Process (5): chromatin organization (GO:0006325), nucleosome assembly (GO:0006334), telomere organization (GO:0032200), epigenetic regulation of gene expression (GO:0040029), gene expression (GO:0010467)

GO Molecular Function (5): DNA binding (GO:0003677), structural constituent of chromatin (GO:0030527), cadherin binding (GO:0045296), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)

GO Cellular Component (8): nucleosome (GO:0000786), extracellular region (GO:0005576), nucleus (GO:0005634), nucleoplasm (GO:0005654), membrane (GO:0016020), protein-containing complex (GO:0032991), extracellular exosome (GO:0070062), chromosome (GO:0005694)

Reactome top-level categories

Rollup of top-12 pathways:

CategoryPathways
Chromatin modifying enzymes5
Epigenetic regulation of gene expression2
Cellular Senescence2
Negative epigenetic regulation of rRNA expression2
Positive epigenetic regulation of rRNA expression2
Signaling by Interleukins1
Pre-NOTCH Expression and Processing1
TCF dependent signaling in response to WNT1
Mitotic Prophase1
Chromatin organization1
Gene Silencing by RNA1
Activation of HOX genes during differentiation1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular anatomical structure3
chromatin2
cellular component organization1
chromatin organization1
nucleosome organization1
protein-DNA complex assembly1
chromosome organization1
chromatin remodeling1
regulation of gene expression1
macromolecule biosynthetic process1
nucleic acid binding1
structural molecule activity1
cell adhesion molecule binding1
protein dimerization activity1
binding1
protein-DNA complex1
intracellular membrane-bounded organelle1
nuclear lumen1
cellular_component1
extracellular vesicle1
intracellular membraneless organelle1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

448 interactions, top by confidence:

ABTypeScore
H3C1CHAF1Apsi-mi:“MI:0914”(association)0.910
NASPH3C1psi-mi:“MI:0915”(physical association)0.910
SUZ12EEDpsi-mi:“MI:0914”(association)0.910
H3C1H4C16psi-mi:“MI:0915”(physical association)0.890
H4C16H3C1psi-mi:“MI:0407”(direct interaction)0.890
H2AC4H2BC11psi-mi:“MI:0915”(physical association)0.850
H3C1RBBP4psi-mi:“MI:0914”(association)0.840
H3C1DNAJC9psi-mi:“MI:0915”(physical association)0.810
NASPH3C1psi-mi:“MI:0915”(physical association)0.780
H3C1NASPpsi-mi:“MI:0915”(physical association)0.780
H3C1HAT1psi-mi:“MI:0914”(association)0.770
H2AZ1ZNHIT1psi-mi:“MI:0914”(association)0.770
H3C1MCM2psi-mi:“MI:0915”(physical association)0.710
H3C1MCM2psi-mi:“MI:0914”(association)0.710
KDM1Apsi-mi:“MI:0915”(physical association)0.700
HTTH3C1psi-mi:“MI:0915”(physical association)0.700

BioGRID (3102): HIST1H3A (Affinity Capture-Western), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3H (Two-hybrid), FBLIM1 (Two-hybrid), HIST1H3A (Reconstituted Complex), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), KAT2B (Co-localization), HIST1H3A (Biochemical Activity)

ESM2 similar proteins: A1CP80, A1D240, A2QRR5, A3LXD5, A4RCX7, A5DFC5, A5DG57, P02299, P07041, P08898, P09988, P0CO04, P0CO05, P10651, P23753, P61832, P61834, P61835, P68431, P68432, P68433, P84227, P84228, P84229, P84230, P84231, P84233, P84234, P84235, P84236, P84237, P84238, P84239, Q0D0E8, Q0UY45, Q1E225, Q28D37, Q2UCQ0, Q4IER8, Q4QRF4

Diamond homologs: A1CP80, A1D240, A2QRR5, A2Y533, A3GHN6, A3LXD5, A4RCX7, A5DFC5, A5DG57, A5DWE2, A5E094, C0HL66, C0HL67, P02299, P02301, P07041, P08903, P09988, P0CO04, P0CO05, P10651, P23753, P59226, P61830, P61831, P61832, P61833, P61834, P61835, P61836, P68427, P68428, P68429, P68430, P68431, P68432, P68433, P69071, P69072, P69073

SIGNOR signaling

75 interactions.

AEffectBMechanism
AURKB“down-regulates activity”H3C1phosphorylation
AURKB“up-regulates activity”H3C1phosphorylation
AURKC“up-regulates activity”H3C1phosphorylation
RPS6KA3“down-regulates activity”H3C1phosphorylation
RPS6KA5“down-regulates activity”H3C1phosphorylation
TGM2unknownH3C1phosphorylation
PBKunknownH3C1phosphorylation
MAML1“down-regulates activity”H3C1acetylation
PIM1“down-regulates activity”H3C1phosphorylation
VRK1unknownH3C1phosphorylation
MAPK14unknownH3C1phosphorylation
PRKCD“up-regulates activity”H3C1phosphorylation
PIM“down-regulates activity”H3C1phosphorylation
KDM6A“down-regulates activity”H3C1demethylation
KDM6B“down-regulates activity”H3C1demethylation
CTNNB1“up-regulates activity”H3C1
“Polycomb repressive complex 2”“up-regulates activity”H3C1methylation
KDM4B“down-regulates activity”H3C1demethylation
KDM4C“down-regulates activity”H3C1demethylation
SETDB2“up-regulates activity”H3C1methylation
KDM5A“up-regulates activity”H3C1demethylation
KDM5B“up-regulates activity”H3C1demethylation
KDM5C“up-regulates activity”H3C1demethylation
KDM5D“up-regulates activity”H3C1demethylation
“Set1-Ash2 HMT complex”“down-regulates activity”H3C1methylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 122 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

PathwayPartnersFoldFDR
Regulation of PTEN gene transcription919.6×1e-07
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known518.3×9e-05
Transcriptional Regulation by E2F6517.9×1e-04
Negative Regulation of CDH1 Gene Transcription1217.6×1e-09
Deposition of new CENPA-containing nucleosomes at the centromere917.4×2e-07
Defective pyroptosis917.2×2e-07
PRC2 methylates histones and DNA916.7×2e-07
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression916.7×2e-07

GO biological processes:

GO termPartnersFoldFDR
heterochromatin formation1024.8×3e-09
nucleosome assembly1621.8×2e-14
chromatin remodeling1510.6×3e-09
chromatin organization1110.6×1e-06
DNA replication69.6×5e-03
DNA repair138.1×1e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

46 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic1
Uncertain significance44
Likely benign1
Benign0

Top pathogenic / likely-pathogenic (1)

Variant IDHGVSClassification
800339NM_003529.3(H3C1):c.400G>C (p.Glu134Gln)Likely pathogenic

SpliceAI

141 predictions. Top by Δscore:

VariantEffectΔscore
6:26020657:G:GTdonor_gain0.9500
6:26020516:G:GTdonor_gain0.8200
6:26020553:GCCAC:Gdonor_gain0.7600
6:26020680:G:GGdonor_gain0.7200
6:26020721:GACTT:Gdonor_gain0.7100
6:26020679:C:CGdonor_gain0.6800
6:26020684:A:Gdonor_gain0.6800
6:26020760:A:AGdonor_gain0.6800
6:26020657:GAA:Gdonor_gain0.6600
6:26020894:G:GTdonor_gain0.6500
6:26020528:TGGC:Tdonor_gain0.6400
6:26020772:G:GTdonor_gain0.6000
6:26020531:C:Tdonor_gain0.5700
6:26020562:G:GTdonor_gain0.5500
6:26020701:T:Adonor_gain0.5500
6:26020893:GGGC:Gdonor_gain0.5500
6:26020516:G:Tdonor_gain0.5400
6:26020696:GC:Gacceptor_gain0.5400
6:26020784:GCC:Gdonor_gain0.5400
6:26020529:G:GAdonor_gain0.5300
6:26020563:C:Tdonor_gain0.5300
6:26020706:C:Adonor_gain0.5300
6:26020793:G:GGdonor_gain0.5200
6:26020549:G:GGdonor_gain0.5100
6:26020548:A:AGdonor_gain0.5000
6:26020500:C:CGdonor_gain0.4900
6:26020695:A:AGacceptor_gain0.4900
6:26020696:G:GGacceptor_gain0.4900
6:26020708:C:Tdonor_gain0.4800
6:26020733:GACC:Gdonor_gain0.4600

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1001157548 (6:26018849 A>T), RS1001751186 (6:26021009 G>A,C), RS1003023837 (6:26021387 A>G,T), RS1004059208 (6:26021135 G>T), RS1004310398 (6:26021224 C>T), RS1004425157 (6:26021369 G>A,C,T), RS1005240998 (6:26018992 C>T), RS1006317873 (6:26020387 C>T), RS1006657746 (6:26020226 G>C), RS1008001463 (6:26020847 A>C,G,T), RS1009094456 (6:26018465 T>G), RS1009313088 (6:26020611 G>A), RS1010320043 (6:26021081 C>T), RS1010329843 (6:26021020 G>A,C,T), RS1012163077 (6:26019825 A>G)

Disease associations

OMIM: gene MIM:602810 | disease phenotypes: MIM:254500

GenCC curated gene-disease

Mondo (1): plasma cell myeloma (MONDO:0009693)

Orphanet (2): Multiple myeloma (Orphanet:29073), AL amyloidosis (Orphanet:85443)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

StudyTraitp-value
GCST004521_113Autism spectrum disorder or schizophrenia3.000000e-19
GCST004521_169Autism spectrum disorder or schizophrenia4.000000e-14
GCST004521_69Autism spectrum disorder or schizophrenia8.000000e-24
GCST004521_83Autism spectrum disorder or schizophrenia1.000000e-13
GCST008075_179HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)2.000000e-10
GCST008075_65HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)1.000000e-10
GCST008084_206HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)6.000000e-10
GCST008084_77HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)8.000000e-11
GCST008085_108HDL cholesterol levels in current drinkers3.000000e-06
GCST010002_50Refractive error4.000000e-34
GCST010142_16Fish- and plant-related diet2.000000e-10
GCST010142_19Fish- and plant-related diet4.000000e-10
GCST010142_34Fish- and plant-related diet7.000000e-09
GCST010142_35Fish- and plant-related diet8.000000e-09
GCST010142_42Fish- and plant-related diet1.000000e-08
GCST010142_7Fish- and plant-related diet3.000000e-12
GCST010702_75Subcortical volume (MOSTest)3.000000e-11
GCST010703_272Brain morphology (MOSTest)7.000000e-16

EFO canonical traits (4, from GWAS)

EFO IDTrait name
EFO:0004612high density lipoprotein cholesterol measurement
EFO:0004329alcohol drinking
EFO:0008111diet measurement
EFO:0004346neuroimaging measurement

MeSH disease descriptors (1)

DescriptorNameTree numbers
D009101Multiple MyelomaC04.557.595.500; C14.907.454.460; C15.378.147.780.650; C15.378.463.515.460; C20.683.515.845; C20.683.780.650

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

3 measured of 6 human assays (6 total across all organisms); most potent 3 below. Values come from heterogeneous assays and are not directly comparable.

LigandMeasureValuePatent
N-hydroxy-3-(2-phenethyl-1-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamideEC50500 nMUS-10201527: Benzimidazole derivatives: preparation and pharmaceutical applications
3-(1-(3-(dimethylamino)-2,2-dimethylpropyl)-2-phenethyl-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamideEC501100 nMUS-10201527: Benzimidazole derivatives: preparation and pharmaceutical applications
N-hydroxy-3-(2-phenethyl-1-(3,4,5-trimethoxybenzyl)-1H-benzo[d]imidazol-5-yl)acrylamideEC501700 nMUS-10201527: Benzimidazole derivatives: preparation and pharmaceutical applications

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
Benzo(a)pyrenedecreases expression, decreases methylation3
sodium arsenitedecreases expression, increases expression2
Air Pollutantsdecreases expression, increases abundance, increases expression2
Cadmium Chlorideincreases expression, increases abundance2
afuresertibdecreases expression1
methyleugenoldecreases expression1
bisphenol Adecreases expression1
2-methyl-4-isothiazolin-3-oneincreases expression1
hydroxyhydroquinoneincreases expression1
thallium sulfatedecreases expression1
tris(1,3-dichloro-2-propyl)phosphatedecreases expression1
ferrous chlorideincreases expression1
versicolorin Adecreases expression1
phenethyl isothiocyanatedecreases expression1
polyhexamethyleneguanidineaffects expression1
CGP 52608affects binding, increases reaction1
monomethylarsonous aciddecreases expression1
dimethylarsinous acidincreases expression1
abrineincreases expression1
licochalcone Bincreases expression1
MT19c compounddecreases expression1
Leflunomidedecreases expression1
Benzenedecreases expression1
Berberinedecreases expression1
Cadmiumincreases abundance, increases expression1
Calcitriolaffects cotreatment, decreases expression1
Cannabidioldecreases expression1
Dichlorodiphenyl Dichloroethyleneincreases expression1
Diazinonincreases methylation1
Doxorubicindecreases expression1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

TrialPhaseStatusTitle
NCT00029224PHASE4COMPLETEDTreatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00104104PHASE4COMPLETEDA Multiple Myeloma Trial in Patients With Bone Metastases
NCT00211211PHASE4COMPLETEDFREE Study - Fracture Reduction Evaluation
NCT00242528PHASE4WITHDRAWNOpen-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
NCT00257114PHASE4COMPLETEDEvaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00352703PHASE4COMPLETEDPROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
NCT00361140PHASE4COMPLETEDBusulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
NCT00622505PHASE4COMPLETEDZoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
NCT00652041PHASE4COMPLETEDBortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
NCT00733538PHASE4COMPLETEDStage I Multiple Myeloma Treatment
NCT01087008PHASE4COMPLETEDZoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
NCT01249690PHASE4UNKNOWNEfficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
NCT01410929PHASE4WITHDRAWNEvaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma
NCT01731886PHASE4COMPLETEDLenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01868828PHASE4UNKNOWNA Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
NCT02268890PHASE4COMPLETEDA Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
NCT02286830PHASE4COMPLETEDProlonged Protection From Bone Disease in Multiple Myeloma
NCT02559154PHASE4UNKNOWNModified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02577783PHASE4UNKNOWNPDD vs PAD to Treat Initially Diagnosed MM
NCT02773550PHASE4TERMINATEDTreatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
NCT02958969PHASE4COMPLETEDApixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
NCT03173092PHASE4TERMINATEDA Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
NCT03619252PHASE4COMPLETEDPneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
NCT03768960PHASE4COMPLETEDA Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
NCT03829371PHASE4ACTIVE_NOT_RECRUITINGSTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT03908138PHASE4UNKNOWNRDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
NCT04217967PHASE4COMPLETEDIxazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
NCT04952766PHASE4COMPLETEDStudy Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
NCT04989140PHASE4UNKNOWNStudy of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
NCT05183139PHASE4WITHDRAWNA Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
NCT05201781PHASE4RECRUITINGA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05429515PHASE4NOT_YET_RECRUITINGEffect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
NCT05511428PHASE4COMPLETEDHome Based Daratumumab Administration for Patients With Multiple Myeloma
NCT05545202PHASE4UNKNOWNA Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
NCT05555329PHASE4COMPLETEDAlternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
NCT05722405PHASE4RECRUITINGIxazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
NCT05855122PHASE4UNKNOWNSafety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
NCT05944783PHASE4NOT_YET_RECRUITINGBioequivalence Studies of Dasatinib 100 Mg
NCT06057402PHASE4RECRUITINGElranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06251076PHASE4RECRUITINGPlan Development for Giving Teclistamab in the Outpatient Setting

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 76

This page pulls from 76 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpatentpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot